Drug Combo Proves Powerful Against Lung Cancer Kings Park NY

A two-drug combination treatment in Kings Park proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

Magdalena Pomykol Petryk
(631) 427-6060
347 Main St
Huntington, NY
Bong Soon Kim
(631) 444-2210
University Hospital L2
Stony Brook, NY
Douglas Edward Gladstone, MD
12 Sunwood Dr
Miller Place, NY
Min Janice Lu, MD
212-263-6485
Hsc T 16 Rppm 020,
Stony Brook, NY
Tiffany Troso-Sandoval, MD
631-623-4100
650 Commack Rd
Commack, NY
Kenneth D Gold
(631) 666-6752
24 E Main St
Bay Shore, NY
Mrudula Shah
(516) 822-4706
528 Old Country Road
Plainview, NY
RICHARD ANCONA, MD
(631) 979-6466
300 E Main Street
Smithtown, NY
Harish Kumar Malhotra, MD
631-751-3000
235 N Belle Mead Rd
East Setauket, NY
Kenneth L Sacks, MD
203-255-4545
425 Post Rd
Fairfield, CT
Data Provided by:
    

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Genetic Clues for Skin Cancer Therapies Kings Park NY
Scientists have isolated a group of genetic mutations involved in the growth of melanoma, the deadliest form of skin cancer. Their work may lead to therapies with existing drugs that target the same mutations. Led by Yardena Samuels of the National Human Genome Research Institute, the research team from the U.S. National Institutes of Health (NIH) sequenced the protein tyrosine kinase (PTK) gene family in tumor and blood samples from people with metastatic melanoma.
- Delayed Prostate Cancer Therapy Kings Park NY
- Side Effect Of Chemotherapy Drugs Kings Park NY
- Hormone Therapy for Breast Cancer Kings Park NY
- Hormone Therapy for Lung Cancer Kings Park NY
- Fungal Infection Treatments Kings Park NY
- Risks for Childhood Cancer Survivors Kings Park NY
- Exercise for Breast Cancer Survival Kings Park NY
- Exercise for Prostate Cancer Kings Park NY